4basebio PLC Profit Margin

The latest profit margin for 88Q.DE is -1114.69% as of December 2025. That compares with -1654.62% in the prior-year period — up 32.6% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside 4basebio PLC's historical trend and sector peers before judging valuation or financial health.

Over the past year, 88Q.DE's profit margin moved from -1654.62% to -1114.69% — a 32.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 4basebio PLC's valuation or profitability profile.

Against Healthcare companies, 88Q.DE currently prints -1114.69% for profit margin, while the sector average sits near 10.58%. That is roughly 10635.4% below the sector mean. Large gaps often invite a closer look at 4basebio PLC's growth, margins, and balance sheet.

Profit Margin shows how effectively 4basebio PLC converts resources into returns. At -1114.69%, 88Q.DE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1654.62% in the prior-year period — up 32.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 88Q.DE's profit margin (-1114.69%), review year-over-year change from -1654.62%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.